We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently introduced SIGNA Sprint, a next-generation ultra-premium 1.5T MRI system at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025, engineered to push the boundaries of traditional MRI performance. With a 65/200 per-axis gradient strength and built-in AI tools, SIGNA Sprint delivers sharp imaging for cardiology and oncology, enabling faster, more accurate diagnostics.
As healthcare providers increasingly prioritize imaging solutions that balance diagnostic power, cost-effectiveness and patient comfort, SIGNA Sprint stands out with its blend of cutting-edge performance and accessibility. Built-in AI technologies streamline workflows while its patient-centric design, including free-breathing capability and AIR Coils, enhances the overall imaging experience. With SIGNA Sprint, GE HealthCare aims to redefine what's possible at 1.5T, expanding clinical capabilities without the added infrastructure demands of higher-field MRI systems.
Likely Trend of GEHC Stock Following the News
Shares of the company moved north 6.1% and closed at $74.11 on Monday following the announcement, primarily due to the U.S.-China trade deal. In the year-to-date period, GEHC shares have lost 5.3% against the industry’s 5.3% growth. The S&P 500 decreased 4.5% in the same time frame.
The launch of SIGNA Sprint positions GE HealthCare to strengthen its premium MRI market presence with a cost-effective, high-performance alternative to 3.0T systems. Its AI-driven capabilities and enhanced diagnostic features make it appealing to hospitals and research institutions, driving adoption and recurring service revenue. This innovation could support sustained revenue growth, improve investor confidence, and enhance long-term stock performance.
Meanwhile, GEHC currently has a market capitalization of $31.99 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%.
Image Source: Zacks Investment Research
More on GEHC’s SIGNA Sprint
SIGNA Sprint is an ultra-premium, wide-bore MRI system designed to deliver imaging power typically found in 3.0T systems on the more accessible 1.5T platform. A FDA 510(k) application is pending for the system, and clearance is expected to expand GEHC’s diagnostic capabilities in cardiology, oncology, and other advanced clinical and research domains. It delivers exceptional diffusion imaging, vital for oncology, and enables crystal-clear visualization of sub-millimetric structures critical in precision care.
SIGNA Sprint’s core advantage lies in its integrated AI technologies, AIR Recon DL, Sonic DL, and AIR x, which enhance image reconstruction, accelerate scan times, and improve diagnostic accuracy. These deep learning tools enable quantitative MRI, offering deeper insights into tissue characteristics, particularly in cardiac imaging, while streamlining workflows and enhancing treatment monitoring. Designed for patient comfort with a 70cm wide bore, free-breathing capabilities, and AIR Coils, SIGNA Sprint combines advanced imaging power with improved patient experience. As demand for scalable MRI solutions rises, particularly in cardiology and oncology, SIGNA Sprint offers a cost-effective, AI-powered system poised to drive both clinical impact and commercial success for GE HealthCare.
At ISMRM 2025, GE HealthCare is expected to showcase its latest MRI innovations, including SIGNA Sprint, which features SIGNA MAGNUS— a high-resolution head-only scanner with advanced gradients. Additionally, Sonic DL 3D, a deep learning-based MRI acceleration technology, and Freelium, a helium-free sealed magnet platform in development to reduce helium reliance, are also expected to be showcased. These advancements highlight GE HealthCare's leadership in MRI technology.
GEHC’s Recent Developments in Imaging Space
In recent months, GEHC has made strategic moves to expand its imaging services and AI capabilities. In March, GEHC unveiled Freelium, a next-generation sealed magnet platform at ECR 2025, designed to revolutionize Magnetic Resonance imaging. The platform uses less than 1% of helium compared to traditional systems, promoting sustainability and expanding access to quality imaging in helium-scarce regions. In January, GEHC partnered with Sutter Health to form a seven-year Care Alliance, enhancing access to innovative imaging services and improving the patient and clinician experience across the Sutter Health network. This collaboration aims to create a more seamless and coordinated healthcare system.
GEHC’s Zacks Rank & Stocks to Consider
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CVS Health has a long-term estimated growth rate of 11.4%. CVS’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech
GE HealthCare Technologies Inc. (GEHC - Free Report) recently introduced SIGNA Sprint, a next-generation ultra-premium 1.5T MRI system at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025, engineered to push the boundaries of traditional MRI performance. With a 65/200 per-axis gradient strength and built-in AI tools, SIGNA Sprint delivers sharp imaging for cardiology and oncology, enabling faster, more accurate diagnostics.
As healthcare providers increasingly prioritize imaging solutions that balance diagnostic power, cost-effectiveness and patient comfort, SIGNA Sprint stands out with its blend of cutting-edge performance and accessibility. Built-in AI technologies streamline workflows while its patient-centric design, including free-breathing capability and AIR Coils, enhances the overall imaging experience. With SIGNA Sprint, GE HealthCare aims to redefine what's possible at 1.5T, expanding clinical capabilities without the added infrastructure demands of higher-field MRI systems.
Likely Trend of GEHC Stock Following the News
Shares of the company moved north 6.1% and closed at $74.11 on Monday following the announcement, primarily due to the U.S.-China trade deal. In the year-to-date period, GEHC shares have lost 5.3% against the industry’s 5.3% growth. The S&P 500 decreased 4.5% in the same time frame.
The launch of SIGNA Sprint positions GE HealthCare to strengthen its premium MRI market presence with a cost-effective, high-performance alternative to 3.0T systems. Its AI-driven capabilities and enhanced diagnostic features make it appealing to hospitals and research institutions, driving adoption and recurring service revenue. This innovation could support sustained revenue growth, improve investor confidence, and enhance long-term stock performance.
Meanwhile, GEHC currently has a market capitalization of $31.99 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%.
Image Source: Zacks Investment Research
More on GEHC’s SIGNA Sprint
SIGNA Sprint is an ultra-premium, wide-bore MRI system designed to deliver imaging power typically found in 3.0T systems on the more accessible 1.5T platform. A FDA 510(k) application is pending for the system, and clearance is expected to expand GEHC’s diagnostic capabilities in cardiology, oncology, and other advanced clinical and research domains. It delivers exceptional diffusion imaging, vital for oncology, and enables crystal-clear visualization of sub-millimetric structures critical in precision care.
SIGNA Sprint’s core advantage lies in its integrated AI technologies, AIR Recon DL, Sonic DL, and AIR x, which enhance image reconstruction, accelerate scan times, and improve diagnostic accuracy. These deep learning tools enable quantitative MRI, offering deeper insights into tissue characteristics, particularly in cardiac imaging, while streamlining workflows and enhancing treatment monitoring. Designed for patient comfort with a 70cm wide bore, free-breathing capabilities, and AIR Coils, SIGNA Sprint combines advanced imaging power with improved patient experience. As demand for scalable MRI solutions rises, particularly in cardiology and oncology, SIGNA Sprint offers a cost-effective, AI-powered system poised to drive both clinical impact and commercial success for GE HealthCare.
At ISMRM 2025, GE HealthCare is expected to showcase its latest MRI innovations, including SIGNA Sprint, which features SIGNA MAGNUS— a high-resolution head-only scanner with advanced gradients. Additionally, Sonic DL 3D, a deep learning-based MRI acceleration technology, and Freelium, a helium-free sealed magnet platform in development to reduce helium reliance, are also expected to be showcased. These advancements highlight GE HealthCare's leadership in MRI technology.
GEHC’s Recent Developments in Imaging Space
In recent months, GEHC has made strategic moves to expand its imaging services and AI capabilities. In March, GEHC unveiled Freelium, a next-generation sealed magnet platform at ECR 2025, designed to revolutionize Magnetic Resonance imaging. The platform uses less than 1% of helium compared to traditional systems, promoting sustainability and expanding access to quality imaging in helium-scarce regions. In January, GEHC partnered with Sutter Health to form a seven-year Care Alliance, enhancing access to innovative imaging services and improving the patient and clinician experience across the Sutter Health network. This collaboration aims to create a more seamless and coordinated healthcare system.
GEHC’s Zacks Rank & Stocks to Consider
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CVS Health has a long-term estimated growth rate of 11.4%. CVS’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%.